Brief: Myriad Genetics To Sell Prenatal Health Testing Business To Labcorp
Tue 13:42
BRIEF-Myriad Genetics To Sell Prenatal Health Testing Business To Labcorp Oct 20 (Reuters) -
MYRIAD GENETICS AND LABCORP ANNOUNCE DEFINITIVE AGREEMENT FOR MYRIAD TO SELL PRENATAL HEALTH TESTING BUSINESS TO LABCORP
TO SELL PRENATAL HEALTH TESTING BUSINESS TO LABCORP FOR $210 MILLION CASH PLUS INVENTORY
LABCORP EXPECTS $160 MILLION REVENUE ADDITION AND SLIGHTLY ACCRETIVE TO ADJUSTED EARNINGS IN YEAR ONE FROM DEAL
DEAL EXPECTED TO CLOSE BY EARLY 2027 PENDING REGULATORY CLEARANCE
Source text: ID:nGNX2hbdCf
Further company coverage: LH.N
((Reutersbriefs@thomsonreuters.com;))
Recent news on Labcorp Holdings
See all newsBrief: Charles River, Labcorp, And FDA Collaborate To Validate New Preclinical Methods For Abuse Potential Assessment
Brief: Labcorp Declares Quarterly Dividend
Myriad jumps after agreeing to sell prenatal health testing business
Brief: Myriad Genetics To Sell Prenatal Health Testing Business To Labcorp
Live Markets: Split US congress after 2026 midterms could boost healthcare stocks, Mizuho says